Frequency of Aspirin Resistance in Ischemic Stroke Patients and Healthy Controls from Colombia

Alejandro Roman-Gonzalez1, Carlos Andrés Naranjo2, Walter D Cardona-Maya1,3

  • 1Grupo de Investigación en Trombosis, Universidad de Antioquia-UdeA, Colombia.

Insights

Aspirin resistance was observed in 7.4% of ischemic stroke patients and 4% of controls, indicating a need for further investigation into secondary stroke prevention strategies.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Aspirin is a cornerstone for secondary stroke prevention.
  • Understanding aspirin resistance is crucial for optimizing patient outcomes.

Purpose of the Study:

  • To determine the prevalence of aspirin resistance in Colombian patients with prior ischemic cerebrovascular disease on aspirin therapy.
  • To explore potential associations between aspirin resistance and clinical factors.

Main Methods:

  • Optic platelet aggregation testing was performed on 350 patients with ischemic strokes and 100 healthy controls.
  • All participants were undergoing aspirin treatment.

Main Results:

  • Aspirin resistance was detected in 7.4% of ischemic stroke patients and 4% of healthy controls.
  • Aspirin resistance showed a significant association with stroke recurrence in univariate analysis (p = 0.004).
  • No association was found between aspirin resistance and smoking, diabetes, or hypercholesterolemia.

Conclusions:

  • Aspirin resistance is a relevant clinical finding in Colombian patients with ischemic stroke.
  • The presence of aspirin resistance warrants further research into its clinical implications for secondary stroke prevention.
Abstract

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
34
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
792
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
432
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
59